Rheumatology Practice Management (RPM) will be providing a valuable new resource to our readers. Beginning in June, we will be featuring a Coding Corner section, with the goal of helping practice managers stay informed of pertinent issues concerning medical billing and coding, denials, and appeal protocols.
The JW modifier is described by Current Procedural Terminology as “drug amount discarded/not administered to any patient.”1 Historically, the Centers for Medicare & Medicaid Services (CMS) allowed Medicare Administrative Contractors (MACs) the discretion to determine whether to require the JW modifier for any claims with discarded drugs or biologicals, and the specific details regarding how the discarded drug or biological information should be documented.
The majority of care managers and social workers already know that prioritizing patients by risk is a critical component of effective care management, but risk can mean different things to different people.
Managing any type of business is tough. You must be organized, efficient, able to keep things running smoothly, and good at making sure a variety of personalities feel like they are staying on track. Managing a medical practice is even harder; you must do all the above, while also serving patients who are dealing with their own issues and concerns.
In early March 2017, American College of Rheumatology (ACR) President Sharad Lakhanpal, MBBS, MD, released a statement asserting the ACR’s position on the controversial American Health Care Act (AHCA).
The following clinical trials represent a selection of key studies that are currently recruiting patients with osteoarthritis for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
Results 1 - 7 of 7